In this article, we will list the Top 5 Stocks Under $5 That Could Triple. Please visit Top 10 Stocks Under $5 That Could Triple if you’d like to see an extended list and how we came up with the top stocks under $5 that could triple.
5. CervoMed Inc. (NASDAQ:CRVO)
CervoMed Inc. (NASDAQ:CRVO) earns a place on our top 10 stocks under $5 that could triple.
On March 17, 2026, CervoMed Inc. (NASDAQ:CRVO) announced results for the fourth quarter and full year 2025. The company highlighted advancements in its neflamapimod program for dementia with Lewy bodies (DLB).
CervoMed Inc. (NASDAQ:CRVO) further reported favorable Phase 2b RewinD-LB data at CTAD 2025 while achieving an agreement with the FDA and international authorities on the design of a Phase 3 trial. This trial is expected to commence in the latter part of 2026. With the start of the EXPERTS-ALS investigation and topline findings from Phase 2a trials in ischemic stroke recovery and primary progressive aphasia, the upcoming calendar remains catalyst-heavy.
In terms of finances, CervoMed Inc. (NASDAQ:CRVO) reported $20.9 million in cash as of December 31, 2025, indicating a runway of roughly six months, with R&D expenses of $21.8 million and a net loss of $27.0 million for the year.
A day later, Boobalan Pachaiyappan of Roth Capital reduced the price target on CervoMed Inc. (NASDAQ:CRVO) from $19 to $11 while keeping a “Buy” rating. The analyst noted that results were largely in line with expectations, but the company may need to raise capital on less favorable terms.
CervoMed Inc. (NASDAQ:CRVO) is a clinical-stage biotechnology firm specializing in CNS-targeted therapeutics, namely, neflamapimod, aimed at neurodegenerative conditions such as dementia with Lewy bodies, stroke rehabilitation, and several other cerebral disorders.
4. Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) is on our list of the top 10 stocks under $5 that could triple.
As of March 17, 2026, Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) remains a preferred choice among analysts, with Wedbush increasing the price target to $14 from $13 and reiterating an “Outperform” rating on the company’s shares. The firm reflected optimism surrounding the company’s clinical pipeline and upcoming catalysts.
As its focus remains on precision oncology, Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)’s recent progress in the silevertinib program has supported the company’s share price performance.
Wedbush analysts noted that, in December 2025, the company had already reported preliminary Phase 2 data on silevertinib in NSCLC patients with uncommon EGFR mutations. The program is moving forward, and further data readouts are expected in the coming months, which remains a key catalyst.
On March 16, 2026, Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) reported financial results for the fourth quarter and full year ended December 31, 2025. The company cited its 60% objective response rate, 86% CNS ORR, and 91% disease control rate from the previously released Phase 2 data, as well as the upcoming developments, which include the future data presentations and the initiation of a randomized Phase 2 GBM trial in Q2 2026. In terms of finances, cash reserves have increased to $128.7 million, net income has risen to $22.4 million, and the company’s runway is expected to extend into the second half of 2028.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies targeting oncogenic mutations, with a focus on brain-penetrant EGFR inhibitors for NSCLC and glioblastoma.
3. ProQR Therapeutics N.V. (NASDAQ:PRQR)
ProQR Therapeutics N.V. (NASDAQ:PRQR) earns a spot in our list of the top 10 stocks under $5 that could triple.
As of March 19, 2026, analysts remain confident in ProQR Therapeutics N.V. (NASDAQ:PRQR), with 100% maintaining “Buy” ratings. The consensus price target of $9.44 implies a 448.56% upside, reflecting growing optimism about the company’s RNA editing platform and future clinical catalysts.
ProQR Therapeutics N.V. (NASDAQ:PRQR) reported full-year 2025 results on March 12, 2026. The company noted the ongoing development of AX-0810 in a Phase 1 trial, with target engagement data anticipated in 1H 2026.
CEO Daniel de Boer described this as a key milestone for ProQR Therapeutics N.V. (NASDAQ:PRQR), which follows pipeline expansion with AX-2402 in Rett syndrome and AX-2911 in MASH. Furthermore, the business received $4.50 million in milestone payments under its agreement with Eli Lilly, providing runway into mid-2027. Early AX-0810 studies showed encouraging pharmacokinetics and safety, with plans to include patients with PSC.
During the quarter, cash decreased to $105.96 million, R&D increased to $51.26 million, and net loss widened to $48.62 million, or $0.46 per share, while ProQR Therapeutics N.V. (NASDAQ:PRQR)’s continued pipeline development remains a central focus for investors.
ProQR Therapeutics N.V. (NASDAQ:PRQR) is a clinical-stage biotechnology company focused on developing RNA therapeutics for severe rare genetic diseases, including inherited retinal impairments, using its patented platform to address unmet medical needs.
2. AtaiBeckley Inc. (NASDAQ:ATAI)
AtaiBeckley Inc. (NASDAQ:ATAI) earns a place on our list of the top 10 stocks under $5 that could triple.
Analysts are strongly supportive of AtaiBeckley Inc. (NASDAQ:ATAI) amid recent clinical updates.
H.C. Wainwright reaffirmed its “Buy” rating and $25.00 price target on March 17, 2026, indicating significant upside from the current $3.65 level.
The recent Phase 2a data for BPL-003 bolstered confidence in AtaiBeckley Inc. (NASDAQ:ATAI)’s pipeline. The findings reinforced the company’s position in the 5-MeO-DMT class by demonstrating that a single dose produces a therapeutic effect that intensifies over time and lasts for at least 12 weeks.
The data, which highlights rising confidence in AtaiBeckley Inc. (NASDAQ:ATAI)’s clinical differentiation of the asset, was cited by the firm as a strong signal that continues to set the benchmark for the class.
AtaiBeckley Inc. (NASDAQ:ATAI), following an end-of-Phase 2 meeting, reached an agreement with the FDA on the dual-trial design for its planned Phase 3 program. This milestone supports the overall momentum and keeps the program on schedule for launch in Q2 2026. Prior to this, BPL-003 was designated as a Breakthrough Therapy in October 2025.
Srinivas Rao, Co-Founder and CEO, stated,
“BPL-003 has demonstrated rapid, durable antidepressant effects, and the FDA’s supportive End-of-Phase 2 feedback enables us to advance into two parallel Phase 3 trials beginning in Q2 2026. With Breakthrough Therapy Designation and a robust pivotal design, we believe BPL‑003 has the potential to meaningfully reshape the treatment landscape for TRD.”
AtaiBeckley Inc. (NASDAQ:ATAI), a clinical-stage biopharmaceutical company, focuses on developing effective, rapid-acting, and convenient mental health treatments.
1. Alight, Inc. (NYSE:ALIT)
Alight, Inc. (NYSE:ALIT) earns a place on our list of the top 10 stocks under $5 that could triple.
As of March 19, 2026, analyst sentiment toward Alight, Inc. (NYSE:ALIT) remains divided, with a consensus price target of $2.00 suggesting a potential upside of 305.40%. The stock fell 79.59% over six months and 88.63% over one year.
The prior day, CEO Rohit Verma highlighted a renewed focus on service excellence and operational execution to stabilize growth when Alight, Inc. (NYSE:ALIT) presented its strategic reset at the KeyBanc Capital Markets Healthcare Forum. Management acknowledged the challenges associated with prior execution and emphasized the consistent client feedback that urged enhanced service and engagement. To resolve this issue, Alight, Inc. (NYSE:ALIT) is deploying artificial intelligence to optimize user experience and automate back-office processes.
Meanwhile, management added that Alight, Inc. (NYSE:ALIT) canceled its dividend to release approximately $145 million for deleveraging, potential share buybacks, and strategic investments. The company also maintains $270 million in cash and a $330 million credit facility. Management’s updated guidance is expected to come out alongside the Q1 earnings release.
Alight, Inc. (NYSE:ALIT) delivers cloud-based human capital and business solutions. With its Alight Worklife platform, the company offers services such as integrated benefits administration, healthcare navigation, financial well-being, leave of absence management, and retiree healthcare.
While we acknowledge the potential of ALIT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ALIT and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 10 Most Active Penny Stocks to Buy.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
